Saturday , July 21 2018
Home / Letter From The Editor / Letter from the Editor, #688

Letter from the Editor, #688

Aug 1, 2013

Over and over we have new therapies for diabetes come to the market with lots of promise and hope. These new classes with great results in pre-marketing studies offer extra armament to fight the epidemic of diabetes yet they don’t get used because of words like "cardiac arrest" and "cancer." In fact, even older medications can fall from favor if studies show them to have an increase in cancer risk. 

We at Diabetes In Control are not trying to make light of something as serious as cancer, but I do have an issue with all the naysayers of these drugs and their vigilant attack on newer agents. We know that there are much stricter requirements for post market drug studies and anytime you follow a group of patients carefully and compare them to unwatched patients there will be different rates of adverse reactions. We have seen this with older medications as well.
This week we have three studies showing that the cancer and cardiovascular risks of glargine, incretin analogs and rosiglitazone have been way overblown. Check out these three items (No Cancer Linked to GLP-1 Compounds, Glargine Does Not Increase Cancer Risk, and Avandia Not Tied to Fatal Cardiac Events) and then decide for yourself.
Often times many of our patients and we as clinicians don’t understand how the different subsets of LDL can affect cardiovascular health and how high or low carbohydrate food choices affect these subsets.  Dr. Ronald Krauss, MD, Senior Scientist and Director of Atherosclerosis Research at Children’s Hospital Oakland Research Institute, got together with our good friend Joy Pape, RN, BSN, CDE to look at Dietary Determinants of Atherogenic Dyslipidemia and Targeting the Culprit Particles.

If you want the best of technology for your patients then you may want to check out this week’s product, the Glucocard Expression meter. It’s big enough for arthritic patients to use, has great software and for those who respond best to sound rather than sight, the ability to talk in either English or Spanish makes this the perfect choice. 


From "Viewer Will Ryan shares what he has learned about having diabetes; dLife takes a trip on the diabetes bus; Jim Turner quizzes our diabetes knowledge on a fact or fiction diabetes testing procedure." Sundays live online at at 7 PM ET, 6 PM CT, and 4 PM PT. Keep up on the latest dLife news at

Please answer this week’s poll: With new studies showing little or no risk of cancer from glargine, incretin mimetics and Avandia, will you recommend them?
We can make a difference!

Dave Joffe, Editor-in-chief